Suraksha Diagnostic Limited — Investor Meet, 14-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Suraksha Diagnostic's Q1 FY26 saw total income rise 18.83% to ₹73.49 Cr, with EBITDA at ₹24.66 Cr (33.97% margin) and PAT at ₹9.18 Cr (19.67% YoY increase). Volume grew ~26% driven by new centers and B2B. The company acquired Fetomat Wellness for genomic medicine entry and launched Suraksha Genomics (₹22 Cr investment), Eastern India's first complete genomic lab. They added 8 centers, reaching 58, targeting 15-18 new centers this year and 100 in 2-3 years. Management expects improved margins as new centers mature, guiding for 15% revenue growth and 34-35% EBITDA margin for FY26. Sentiment is confident, focused on strategic expansion.